ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 212

Distinctive Characteristics of Anti-Mi-2 and –p155/140 Autoantibody Production in Two Cohorts of Mexican Patients with Dermatomyositis

Monica Vazquez-Del Mercado1, Marcelo Petri1, Luis J. Jara-Quezada2, Miguel A. Saavedra-Salinas3, Claudia Cruz-Reyes4, Olga-Lidia Vera-Lastra5, Lilia Andrade6, Mario Salazar-Paramo7, Laura Gonzalez-Lopez8, Jorge Gamez-Nava9, Rosa E. Prieto-Parra7, Teresita Martin Marquez1, Jason Y.F. Chan10, Edward K.L. Chan11 and Minoru Satoh10, 1Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, 2Direction of Education and Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, 3Rheumatology, Centro Médico Nacional, México, Mexico, 4Centro Medico La Raza Instituto Mexicano del Seguro Social Mexico D.F., Mexico D. F., Mexico, 5Rheumatology, Inst Mexicano Seguro Social, Mexico City, Mexico, 6CMN 20 Noviembre ISS STE, Mexico, Mexico, 7Clinical Research Division, Instituto Mexicano Del SS, Guadalajara, Mexico, 8Departamento de Medicina Interna/Rheumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico, 9Rheumatology, Centro Medico de Occidente, Guadalajara Jal, Mexico, 10Medicine, University of Florida, Gainesville, FL, 11Oral Biology, University of Florida, Gainesville, FL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Autoantibodies and myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Clinical and Therapuetic Aspects of Idiopathic Inflammatory Myopathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Various autoantibodies associated with a unique subset of polymyositis/dermatomyositis (PM/DM), including antibodies to Jo-1 and other synthetases, SRP, Mi-2, PM-Scl and others, have been described. Specificities of autoantibodies and associated clinical manifestations in PM/DM are known to be affected by both genetic and environmental factors. In particular high prevalence of DM and anti-Mi-2 in Central America is thought to be associated with high UV index of the area. Prevalence of autoantibodies and clinical manifestation in PM/DM patients were evaluated comparing two cohorts in Mexico  

Methods: Ninety-five Mexican patients with PM/DM (66 DM, 29 PM; 67 Mexico City, 28 Guadalajara) were studied. Autoantibodies recognized by sera were characterized based on protein analysis by immunoprecipitation using 35S-methionine labeled K562 cell extract and RNA analysis in immunoprecipitates by urea-PAGE and silver staining. Clinical information was from database and chart review.

Results:

DM was 69% in Mexican PM/DM and anti-Mi-2 was the most common autoantibody specificity (35%), followed by anti-p155/140 (11%); however, anti-Jo-1 that is the most common in most PM/DM studies was only 4%. DM was more common and comparable in both Mexico City and Guadalajara (69% and 71%, respectively).  However, autoantibody profile in DM of Mexico City vs Guadalajara showed striking difference; anti-Mi-2 was 59% vs 15% (P = 0.001) whereas anti-p155/140 was 9% vs 30% (P = 0.05), respectively. Thus, despite comparable DM dominance and similar UV index in two areas, prevalence of anti-Mi-2 was very high (59%) in Mexico City but not in Guadalajara (15%), suggesting a role of factors other than UV. Reported differences in genetic background of Mexican-Mestizo in these two areas (higher percentage of Amerindian derived genes in Mexico City vs European derived gene dominance in Guadalajara area) may be related to the difference in prevalence of autoantibodies.  Clinical feature of anti-Mi-2(+) DM (n = 30) vs anti-Mi-2(-) DM (n = 36) was compared.  Male was more common in anti-Mi-2(+) vs (-) (37% vs 22%,P=0.27). Shawl sign (86% vs 62%, p=0.0002) and weight loss (59% vs 45%, p=0.30) were more common in anti-Mi-2(+) DM than anti-Mi-2(-) DM. High CPK (> 2000) (88% vs 35%, p= 0.0001) was more common in anti-Mi-2(+) and levels of muscle enzymes were higher in anti-Mi-2(+) group than anti-Mi-2(-) group (CPK p = 0.0001, LDH p = 0.001).

Conclusion: Anti-Mi-2 is at high prevalence in Mexican DM and associated with male, shawl sign, and high CPK. Prevalence of anti-Mi-2 and anti-p155/140 was significantly different in Mexico City vs Guadalajara, suggesting roles of factors other than UV in DM autoantibody production. Significant difference in clinical features of DM within a same country need to be carefully evaluated and the role of environmental and genetic factors will need further studies.

PM/DM DM

DM

Mexico City

DM

Guadalajara

PM
N= 95 66 46 20 29
Autoantibodies
Mi-2 35% 45% 59%1 15%1 10%
p155/140 11% 15% 9%2 30%2 0%
Jo-1 4% 3% 4% 0% 7%
Myositis specific antibodies negative 36% 21% 15% 35% 69%

1, p=0.001; 2, p=0.056 by Fisher exact test


Disclosure:

M. Vazquez-Del Mercado,
None;

M. Petri,
None;

L. J. Jara-Quezada,
None;

M. A. Saavedra-Salinas,
None;

C. Cruz-Reyes,
None;

O. L. Vera-Lastra,
None;

L. Andrade,
None;

M. Salazar-Paramo,
None;

L. Gonzalez-Lopez,
None;

J. Gamez-Nava,
None;

R. E. Prieto-Parra,
None;

T. Martin Marquez,
None;

J. Y. F. Chan,
None;

E. K. L. Chan,
None;

M. Satoh,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinctive-characteristics-of-anti-mi-2-and-p155140-autoantibody-production-in-two-cohorts-of-mexican-patients-with-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology